Skip to search formSkip to main contentSkip to account menu

PM-SCL extractable nuclear Ab:ACnc:Pt:Ser:Qn

Known as: PM-SCL ????? ??:?????:???:??:???, PM-SCL ekstractable nuclear Ab:SçKons:Zml?:Ser:Kant, PM-SCL nucléaire soluble Ac:Concentration arbitraire:Temps ponctuel:Sérum:Quantitatif 
National Institutes of Health

Related topics

Related topics

6 relations
ACncAntibodiesExtractable nuclear antibodySerology (antibodies and most antigens except blood bank and infectious agents)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
A novel variable flux memory machine with series hybrid magnets
This paper proposes a novel variable flux memory (VFM) machine, in which the “constant” permanent magnet (PM) (CPM) with high… 
Highly Cited
2015
Highly Cited
2015
Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Highly Cited
2014
Highly Cited
2014
Demonstration of an 8-dimensional modulation format with reduced inter-channel nonlinearities in a polarization multiplexed coherent system.
We demonstrate a polarization-managed 8-dimensional modulation format that is time domain coded to reduce inter-channel… 
Highly Cited
2011
Highly Cited
2011
Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone.
OBJECTIVE Exposure to supraphysiologic levels of glucocorticoid drugs is known to have detrimental effects on bone formation and… 
Highly Cited
2011
Highly Cited
2011
Spindle positioning in human cells relies on proper centriole formation and on the microcephaly proteins CPAP and STIL
Patients with MCPH (autosomal recessive primary microcephaly) exhibit impaired brain development, presumably due to the… 
Highly Cited
2010
Highly Cited
2010
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats
The purpose of this study was to evaluate the effects of sclerostin inhibition by treatment with a sclerostin antibody (Scl‐AbII… 
Highly Cited
2009
Highly Cited
2009
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
The development of bone‐rebuilding anabolic agents for potential use in the treatment of bone loss conditions, such as… 
Highly Cited
2009
Highly Cited
2009
A Short Treatment With an Antibody to Sclerostin Can Inhibit Bone Loss in an Ongoing Model of Colitis
Chronic inflammation leads to bone loss, and increased fracture rates have been reported in a number of human chronic… 
Highly Cited
2007
Highly Cited
2007
Tonic and phasic electrodermal measures of human aversive conditioning with long duration stimuli.
Two experiments investigated phasic and tonic electrodermal responding to long, variable-duration stimuli in aversive… 
Highly Cited
1982
Highly Cited
1982
Partitioning of pulmonary vascular resistance in dogs by arterial and venous occlusion.
We perfused in situ isolated left lower lung lobes at a steady flow rate in zone 3 condition. When the lobar arterial inflow was… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)